Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/ II Trial to Assess the Safety and Efficacy of CXD101 in Combination With the PD-1 Inhibitor Nivolumab in Patients With Metastatic, Previously-Treated, Microsatellite-Stable Colorectal Carcinoma

NCT03993626 is registered in ClinicalTrials.gov with Celleron Therapeutics Ltd. as lead sponsor.

NCT NCT03993626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03993626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/ II Trial to Assess the Safety and Efficacy of CXD101 in Combination With the PD-1 Inhibitor Nivolumab in Patients With Metastatic, Previously-Treated, Microsatellite-Stable Colorectal Carcinoma
Lead sponsor
Celleron Therapeutics Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 22, 2018
Completion date
June 15, 2020
Enrollment
55 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms malignant